Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd increased its holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) by 28.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,260 shares of the biopharmaceutical company’s stock after acquiring an additional 4,900 shares during the quarter. WINTON GROUP Ltd owned approximately 0.07% of Intercept Pharmaceuticals worth $307,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Pictet Asset Management SA lifted its stake in shares of Intercept Pharmaceuticals by 10.4% in the second quarter. Pictet Asset Management SA now owns 157,293 shares of the biopharmaceutical company’s stock worth $2,172,000 after acquiring an additional 14,768 shares in the last quarter. Monaco Asset Management SAM bought a new stake in Intercept Pharmaceuticals in the second quarter valued at about $414,000. SG Americas Securities LLC bought a new stake in Intercept Pharmaceuticals in the second quarter valued at about $1,562,000. Clear Creek Financial Management LLC bought a new stake in Intercept Pharmaceuticals in the second quarter valued at about $176,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Intercept Pharmaceuticals by 7.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 106,868 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 7,019 shares during the last quarter. Institutional investors and hedge funds own 86.00% of the company’s stock.

Intercept Pharmaceuticals Stock Performance

Shares of NASDAQ ICPT opened at $15.10 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.46 and a debt-to-equity ratio of 2.07. The stock has a 50 day simple moving average of $14.99 and a 200-day simple moving average of $15.53. The company has a market cap of $625.40 million, a PE ratio of 2.63 and a beta of 1.14. Intercept Pharmaceuticals, Inc. has a 12-month low of $10.81 and a 12-month high of $21.25.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Piper Sandler lowered their price objective on Intercept Pharmaceuticals from $82.00 to $49.00 in a report on Friday, September 30th. Robert W. Baird lowered their price objective on Intercept Pharmaceuticals from $52.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, October 3rd. B. Riley lowered their price objective on Intercept Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating for the company in a report on Monday, August 22nd. Raymond James boosted their price objective on Intercept Pharmaceuticals from $23.00 to $26.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Finally, Cowen lowered their target price on Intercept Pharmaceuticals to $22.00 in a report on Tuesday, August 9th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.80.

Intercept Pharmaceuticals Profile

(Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

See Also

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.